Back to Search
Start Over
Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
- Source :
- International Journal of Molecular Sciences, Vol 13, Iss 12, Pp 16020-16045 (2012), International Journal of Molecular Sciences
- Publication Year :
- 2012
- Publisher :
- MDPI AG, 2012.
-
Abstract
- Drug conjugates have been studied extensively in preclinical in vitro and in vivo models but to date only a few compounds have progressed to the clinical setting. This situation is now changing with the publication of studies demonstrating a significant impact on clinical practice and highlighting the potential of this new class of targeted therapies. This review summarizes the pharmacological and molecular background of the main drug conjugation systems, namely antibody drug conjugates (ADCs), immunotoxins and immunoliposomes. All these compounds combine the specific targeting moiety of an antibody or similar construct with the efficacy of a toxic drug. The aim of this strategy is to target tumor cells specifically while sparing normal tissue, thus resulting in high efficacy and low toxicity. Recently, several strategies have been investigated in phase I clinical trials and some have entered phase III clinical development. This review provides a detailed overview of various strategies and critically discusses the most relevant achievements. Examples of the most advanced compounds include T-DM1 and brentuximab vedotin. However, additional promising strategies such as immunotoxins and immunoliposmes are already in clinical development. In summary, targeted drug delivery by drug conjugates is a new emerging class of anti-cancer therapy that may play a major role in the future.
- Subjects :
- Drug
Immunoconjugates
media_common.quotation_subject
medicine.medical_treatment
Antineoplastic Agents
Review
Pharmacology
Ado-Trastuzumab Emtansine
Antibodies, Monoclonal, Humanized
Catalysis
Targeted therapy
Inorganic Chemistry
lcsh:Chemistry
Trastuzumab
In vivo
Immunotoxin
Neoplasms
medicine
Animals
Humans
Maytansine
Physical and Theoretical Chemistry
Brentuximab vedotin
Molecular Biology
lcsh:QH301-705.5
Spectroscopy
media_common
Brentuximab Vedotin
antibody drug conjugates
business.industry
Organic Chemistry
General Medicine
targeted therapy
Computer Science Applications
Clinical trial
immunotoxins
Targeted drug delivery
lcsh:Biology (General)
lcsh:QD1-999
Liposomes
drug conjugates
immunoliposomes
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 14220067
- Volume :
- 13
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- International Journal of Molecular Sciences
- Accession number :
- edsair.doi.dedup.....9af2070413699b2fd3710a2c4b113c51